Alpha-1 antitrypsin deficiency and liver disease

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

SERPINA1 alleles are codominantly expressed and named by their electrophoretic mobility. Normal M protein is secreted efficiently. Z protein is retained in hepatocyte endoplasmic reticulum, where polymer accumulation can trigger inflammation, fibrosis and carcinogenesis. The same retention produces low blood and alveolar levels, reducing protection from proteases and predisposing to early panacinar emphysema, especially with smoking. Lung and liver burdens therefore arise by different mechanisms and do not necessarily progress together.

The phenotype is variable. Some Pi*ZZ infants develop jaundice and pale stools yet recover biochemically; a minority progress in childhood, while others present decades later. Metabolic dysfunction, alcohol and male sex are recognised modifiers, but individual prediction remains imprecise. Heterozygous Pi*MZ should not be treated as harmless when substantial steatotic or alcohol-related liver disease exists, nor should it automatically be blamed for every abnormal test. A complete aetiology screen remains necessary.

Diagnosis requires confirmation beyond a single serum level. Inflammation, pregnancy and oestrogens increase A1AT, while protein loss and severe liver failure can lower it. Phenotyping demonstrates circulating variants but transfusion and rare null alleles complicate interpretation; genotyping identifies common or broader SERPINA1 changes under genomic criteria. Liver management centres on fibrosis assessment, avoidance of smoking and harmful alcohol, metabolic treatment, vaccination and standard surveillance for cirrhosis. Liver transplant replaces the source of abnormal protein and corrects the recipient's circulating phenotype, whereas lung disease may remain.

Key points

Alpha-1 antitrypsin is produced mainly by hepatocytes and protects lung connective tissue from neutrophil elastase.
The common Z variant misfolds and polymerises within hepatocytes, causing toxic gain-of-function liver injury while low circulating protein creates loss-of-function lung risk.
Severe Pi*ZZ disease can present as neonatal cholestasis, childhood fibrosis or adult cirrhosis and hepatocellular carcinoma, with widely variable penetrance.
Pi*MZ and Pi*SZ states carry lower average liver risk but can modify fibrosis when alcohol, obesity, diabetes or another liver disease is present.
Serum A1AT is an acute-phase reactant; inflammation can conceal deficiency and a concentration alone cannot define genotype or hepatic risk.
Confirm a low or suspicious level with phenotype or SERPINA1 genotyping through the current NHS genomic pathway.
Liver tests may be normal despite advanced fibrosis, so elastography, platelet count and imaging matter more than reassurance from ALT alone.
Smoking avoidance is the most important preventable pulmonary intervention, and occupational dust or fume exposure should also be reduced.
Intravenous A1AT augmentation does not remove hepatic polymers and NICE does not recommend replacement therapy for COPD in the UK.
There is no established routine liver-specific medicine; treat cofactors and cirrhosis, coordinate respiratory care and refer advanced disease for transplantation.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Pathogenic SERPINA1 variants

Inherited SERPINA1 variants, especially the Z allele in severe genotypes, cause alpha-1 antitrypsin misfolding and reduced circulating protein.

Heterozygous susceptibility

Pi*MZ and Pi*SZ states usually carry lower average liver risk but can amplify fibrosis when another hepatic injury is present.

Environmental cofactors

Smoking strongly accelerates lung damage, while alcohol, obesity, diabetes and other liver disease can increase hepatic expression and progression.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Hepatocyte retention
Misfolded Z alpha-1 antitrypsin polymerises within the endoplasmic reticulum of hepatocytes rather than being secreted normally.
2
Toxic hepatic injury
Intracellular polymer accumulation causes cellular stress, inflammation and variable progressive fibrosis through a toxic gain-of-function mechanism.
3
Loss of lung protection
Low circulating antiprotease activity leaves alveolar tissue vulnerable to neutrophil elastase, causing panacinar emphysema that smoking accelerates.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Neonatal hepatic presentationRed flag

Prolonged conjugated jaundice, hepatomegaly, pale stool, poor growth or coagulopathy occurs in infancy after urgent obstructive and metabolic causes are considered.

Adult silent fibrosis

Thrombocytopenia, splenomegaly, nodular imaging or increased liver stiffness reveals advanced disease despite few symptoms and modest aminotransferases.

Pulmonary deficiency phenotype

Early emphysema, disproportionate basal panacinar change or airflow obstruction in a non-smoker or young smoker prompts A1AT testing and liver assessment.

Mixed liver-risk phenotype

A Pi*MZ or Pi*SZ adult develops fibrosis in the presence of obesity, diabetes, steatosis or alcohol, indicating interacting rather than mutually exclusive causes.

Decompensated chronic liver diseaseRed flag

Ascites, variceal bleeding, jaundice, sarcopenia, encephalopathy or kidney dysfunction requires urgent cirrhosis care and transplant review.

Panniculitis or rare systemic clue

Painful oily-draining subcutaneous nodules are an uncommon deficiency manifestation and should prompt specialist dermatology and respiratory-liver assessment.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Serum alpha-1 antitrypsin concentrationFirst step
Why
Screen for reduced circulating protein in unexplained liver or early lung disease.
Interpretation and limitations
Use the laboratory range and concurrent CRP. An apparently normal level during inflammation may hide a deficient variant, while a low result needs phenotype or genotype confirmation.
02
A1AT phenotype or SERPINA1 genotype
Why
Define the inherited variant and support family assessment.
Interpretation and limitations
Pi*ZZ carries the greatest common severe deficiency risk; Pi*SZ and Pi*MZ modify risk. Discordant level and phenotype may require broader sequencing or deletion analysis through genomic services.
03
Liver biochemical and synthetic profile
Why
Assess active injury and functional reserve.
Interpretation and limitations
ALT and gamma-GT can fluctuate or be normal in advanced fibrosis. Bilirubin, albumin, INR and platelet trajectory better expose decompensation or portal disease.
04
Transient elastography and fibrosis score
Why
Estimate clinically significant fibrosis non-invasively.
Interpretation and limitations
Interpret stiffness alongside inflammation, cholestasis, body habitus and platelets. An elevated or rising result warrants hepatology assessment rather than diagnosis from a single cut-off.
05
Hepatobiliary ultrasonography
Why
Assess morphology, spleen, portal vein, ascites and focal lesions.
Interpretation and limitations
A nodular liver or splenomegaly stages disease; a focal lesion in a cirrhotic liver enters the HCC pathway. Normal morphology does not exclude early fibrosis.
06
Spirometry and gas-transfer assessment
Why
Identify obstructive lung disease and establish respiratory baseline.
Interpretation and limitations
Post-bronchodilator obstruction, hyperinflation and reduced transfer factor quantify pulmonary expression; high-resolution CT is selected by respiratory specialists when it changes management.
07
Liver biopsy with PAS-D staining
Why
Clarify unexplained liver disease or mixed aetiology when non-invasive assessment is insufficient.
Interpretation and limitations
PAS-positive diastase-resistant globules support hepatocellular retention but distribution can be patchy and similar inclusions occur in other settings. Histology does not replace genotype.
08
Family cascade testing
Why
Identify relatives with severe or modifying genotypes and enable prevention.
Interpretation and limitations
Offer informed testing through genetics or specialist pathways, pairing genotype with smoking, lung and liver counselling rather than giving a deterministic prognosis.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Metabolic or alcohol-related liver disease

Cardiometabolic factors, alcohol history and imaging may reveal a commoner primary cause, though these injuries can compound alpha-1 antitrypsin-related fibrosis.

Autoimmune or cholestatic disease

Autoantibodies, immunoglobulins and bile-duct imaging distinguish autoimmune hepatitis, PBC or PSC when the biochemical pattern is not clearly explained.

Other inherited liver disease

Copper studies, iron indices and age-appropriate genetics help distinguish Wilson disease or haemochromatosis from unexplained familial liver injury.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01ConfirmationMove from level to genotypeFirst stepA1AT is low or clinical suspicion remains despite a borderline concentration.

1Check CRP, liver synthesis and protein-loss context and repeat a potentially inflammation-confounded concentration when appropriate.
2Request phenotype or common SERPINA1 genotyping under the current NHS pathway and seek broader analysis if results do not explain the level or phenotype.
3Assess both organs with liver fibrosis testing and respiratory history, spirometry and smoking exposure instead of referring to only one specialty.
4Explain codominant inheritance and variable penetrance and offer proportionate family testing with reproductive and insurance questions directed to genetics.

02Liver protectionReduce modifiers and stage complicationsA severe or modifying A1AT genotype is confirmed with current or potential liver involvement.

1Assess alcohol, weight, diabetes, lipids, viral hepatitis, medicines and other liver causes and avoid attributing all injury to A1AT retention.
2Support smoking cessation, healthy weight, alcohol reduction or abstinence matched to fibrosis and hepatitis A and B vaccination where non-immune.
3Use elastography, platelets and imaging to identify advanced fibrosis, then enter cirrhosis HCC and portal surveillance if present.
4Refer decompensation, progressive portal disease or concerning HCC features to a liver-transplant service without waiting for lung decline.

03Pulmonary careTreat lung disease through the COPD pathwayAirflow obstruction or emphysema accompanies confirmed A1AT deficiency.

1Prioritise complete smoking cessation and reduce occupational dust or fume exposure, offering licensed cessation support.
2Use bronchodilators, pulmonary rehabilitation, vaccination and exacerbation care according to NICE COPD recommendations and the actual spirometric phenotype.
3Do not offer intravenous A1AT replacement routinely in the UK, and do not represent augmentation as a treatment for hepatic polymer accumulation.
4Coordinate oxygen, lung-volume, transplant or trial referral through a specialist respiratory service while maintaining independent liver surveillance.

04DecompensationUse standard liver rescue and transplant pathwaysAscites, encephalopathy, variceal haemorrhage, jaundice or HCC develops.

1Admit acute decompensation, look actively for infection, bleeding, alcohol, medicines and portal thrombosis and apply the BSG/BASL first-day bundle.
2Treat ascites, encephalopathy, varices and nutrition according to cirrhosis guidance rather than searching for an unlicensed polymer-clearing drug.
3Review lung function and cardiovascular status as part of transplant work-up without allowing stable emphysema to block timely referral automatically.
4After transplantation continue respiratory follow-up because the new liver corrects protein production but cannot reverse established emphysema.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Prevents the most important avoidable acceleration of emphysema in A1AT deficiency and reduces broader cardiovascular and cancer harm.

Licensed smoking-cessation pharmacotherapy

Select nicotine replacement, varenicline, cytisinicline or another current NICE-supported option at its BNF regimen according to dependence, contraindications, pregnancy and local service availability, combined with behavioural support.

Match adverse effects, renal function, mental-health history and interactions to the chosen medicine. Pharmacotherapy does not replace continued follow-up or occupational exposure reduction.

Treats demonstrated airflow obstruction and exacerbation risk but does not change hepatic A1AT polymer accumulation.

Inhaled COPD therapy

Use short- and long-acting bronchodilator or inhaled corticosteroid combinations only according to the current NICE NG115 symptom, exacerbation and spirometry pathway, with inhaler teaching and review.

Check technique, adherence, tachycardia, tremor, urinary retention, glaucoma and pneumonia or oral candidiasis risk by class. Do not prescribe inhaled corticosteroid solely because the genotype is Pi*ZZ.

Raises circulating antiprotease activity for pulmonary deficiency in some jurisdictions but is not a treatment for A1AT-related liver injury.

Intravenous alpha-1 proteinase inhibitor augmentation

Do not offer routinely for COPD in the NHS under NICE NG115; any research or exceptional-access use belongs to a commissioned specialist respiratory pathway and product-specific protocol.

It cannot remove hepatocyte Z polymers and should never delay fibrosis surveillance or transplant referral. Consider plasma-derived product, infusion and access risks only within formal specialist governance.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Cirrhosis and portal hypertension

Progressive hepatic fibrosis may cause ascites, varices, encephalopathy and transplant need despite widely variable penetrance within the same genotype.

Hepatocellular carcinoma

Established advanced fibrosis or cirrhosis increases primary liver cancer risk, linking staging to the appropriate surveillance pathway.

Emphysema and respiratory failure

Severe circulating deficiency can produce early obstructive lung disease, exercise limitation and eventual respiratory failure, particularly with tobacco exposure.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Trend liver tests, platelets and fibrosis measures at an interval based on genotype, age, cofactors and baseline stage rather than relying on symptoms.
For cirrhosis arrange six-monthly ultrasound HCC surveillance, portal-hypertension review, vaccination, nutrition and bone assessment under NICE and BSG guidance.
Repeat spirometry and respiratory review according to obstruction severity, exacerbations and smoking status, with urgent reassessment for rapid functional decline.
Record alcohol, weight, waist, diabetes and lipid control because metabolic or alcohol injury can determine liver trajectory in heterozygous states.
Review family testing and smoking counselling after major life changes and ensure relatives understand that genotype does not predict a fixed outcome.
After liver transplant continue lung surveillance, exposure avoidance and respiratory treatment because established pulmonary structural damage persists.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

One protein, two mechanisms

Hepatic injury results from retained abnormal protein, while lung injury results from too little circulating antiprotease protection.

Inflammation can conceal deficiency

As an acute-phase reactant A1AT rises during illness, so a borderline normal concentration should be revisited when clinical suspicion is strong.

MZ can be a modifier

A single Z allele rarely acts alone like Pi*ZZ but can amplify fibrosis from alcohol or metabolic steatotic liver disease.

Normal ALT is not normal architecture

Advanced portal disease may coexist with modest enzymes, making platelets, stiffness and imaging essential in adult follow-up.

Augmentation cannot clean the liver

Replacing circulating protein addresses a pulmonary deficiency concept and does not remove toxic polymers already retained in hepatocytes.

11Common pitfallsFrequent interpretation and management errors.

01
Excluding A1AT deficiency because the serum concentration is normal during infection or inflammation.
02
Diagnosing genotype from the concentration alone without phenotype or SERPINA1 confirmation.
03
Attributing all fibrosis in a Pi*MZ carrier to the allele and failing to treat alcohol or metabolic cofactors.
04
Reassuring from normal aminotransferases despite falling platelets, increased stiffness or splenomegaly.
05
Offering intravenous augmentation as a treatment for liver disease or outside current UK respiratory guidance.
06
Stopping liver surveillance after transplantation without continuing independent care of established emphysema.